The 'Skinny' On Lilly’s New FDA Approved $15 Billion Pill
Eli Lilly (NYSE: LLY) said the U.S. Food and Drug Administration approved Foundayo, a once-daily GLP-1 pill for obesity, giving the drugmaker a new oral product as competition expands in the weight-loss drug market.
Lilly said Foundayo will begin shipping Monday through its LillyDirect platform and will reach pharmacies and telehealth channels shortly afterward. Patients with insurance coverage may be able to pay $25 per month using a company coupon, while cash-paying patients will pay between $149 and $349 depending on dose. The approval follows Lilly’s recent filing under an FDA expedited review pathway reserved for drugs considered national priorities. The launch puts Foundayo on the market roughly three months after Novo Nordisk introduced its oral Wegovy, setting up a new phase of competition between the two companies in obesity treatment.
Lilly Chief Executive Dave Ricks said the pill is not as effective as the company’s injectable weight-loss medicine Zepbound, but said the oral format could appeal to patients seeking convenience, easier daily use, or a lower-cost option. He also said the product could be used by some patients for weight maintenance after reaching target weight on an injectable therapy.
Foundayo is based on the molecule orforglipron, which Lilly licensed from Japan’s Chugai in 2018 for $50 million upfront in exchange for global rights. In clinical data cited by the company, the pill produced about 12.4% average weight loss among patients who remained on treatment, compared with about 16.6% in a late-stage trial for Novo’s oral Wegovy. Lilly’s Zepbound has shown weight loss of more than 20% in prior studies.
Ricks said Lilly sees Foundayo as a product that can be manufactured and distributed more broadly than injectable GLP-1 medicines because it is a small-molecule drug rather than a peptide. Unlike injectable products that require more complex manufacturing and cold-chain handling, Foundayo can be scaled more easily for global supply, he said. Lilly expects approvals in more than 40 countries over the next year and said it has invested more than $55 billion in manufacturing since 2020, including capacity tied to the pill.
Novo has reported stronger-than-expected early demand for its oral Wegovy, with more than 600,000 prescriptions in March. Novo Chief Executive Mike Doustdar said earlier this year that the pill appeared to expand the obesity-treatment market by bringing in new patients rather than shifting existing users from injections. Ricks said Lilly sees a similar opportunity and is focused on offering multiple treatment options.
The two companies are entering the market with similar starting prices. The lowest doses of both Foundayo and oral Wegovy will cost $149 for cash-paying patients under an agreement reached with the Trump administration last fall. Lilly also said seniors on Medicare will be able to access Foundayo and other GLP-1 obesity medicines for $50 per month beginning this summer through arrangements tied to that deal.
Analysts estimate Foundayo sales will reach $14.79 billion by 2030, according to FactSet. That compares with projected sales of $24.68 billion for Zepbound and $44.87 billion for Mounjaro, Lilly’s diabetes treatment that is also sold for obesity and diabetes outside the United States.
Investors are also watching Lilly’s broader obesity pipeline. The company is awaiting additional data from retatrutide, a more potent weight-loss injection that could further expand its lineup of obesity medicines. Analysts have said Foundayo’s launch and early prescription trends may be important for Lilly shares, which are down about 14% this year.
About Eli Lilly
Eli Lilly and Company (NYSE: LLY), founded in 1876 and based in Indianapolis, Indiana, is a pharmaceutical company that develops and markets medicines across areas including diabetes, obesity, oncology, immunology, and neuroscience.
At the time of publishing, Stocks.News does not hold positions in companies mentioned in the article.